{"id":745075,"date":"2015-11-15T00:00:00","date_gmt":"2015-11-15T00:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/"},"modified":"2025-11-07T01:24:47","modified_gmt":"2025-11-07T06:24:47","slug":"merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/","title":{"rendered":"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir\/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy"},"content":{"rendered":"<p class=\"bwalignc\">       Results from C-EDGE CO-STAR Presented at The Liver Meeting<sup>\u00ae<\/sup>        Show High Sustained Virologic Response After 12 Weeks of Treatment     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of results from the company\u2019s Phase 3 <i>C-EDGE<br \/>\n      CO-STAR<\/i> clinical trial evaluating the efficacy and safety of the<br \/>\n      investigational once-daily tablet elbasvir\/grazoprevir<sup>1<\/sup><br \/>\n      (50mg\/100mg) in patients with chronic hepatitis C virus (HCV) genotypes<br \/>\n      (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid<br \/>\n      agonist therapy (OAT). Ninety-five percent (189\/198) of patients treated<br \/>\n      with elbasvir\/grazoprevir for 12 weeks in the pre-specified primary<br \/>\n      efficacy analysis population achieved sustained virologic response 12<br \/>\n      weeks after the completion of treatment (SVR12, considered virologic<br \/>\n      cure). Adherence to treatment was high, with 97 percent of patients<br \/>\n      taking at least 95 percent of their study medication over the 12 weeks<br \/>\n      of therapy. These findings will be featured today at the American<br \/>\n      Association for the Study of Liver Diseases\u2019 President\u2019s Press<br \/>\n      Conference at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aasld.org%2Fevents-professional-development%2Fliver-meeting&amp;esheet=51224839&amp;newsitemid=20151114005005&amp;lan=en-US&amp;anchor=The+Liver+Meeting%C2%AE&amp;index=1&amp;md5=0343251c869829be7bdda682875425e6\" rel=\"nofollow\">The<br \/>\n      Liver Meeting<sup>\u00ae<\/sup><\/a> and presented in an oral session on<br \/>\n      Sunday, November 15 (Abstract #40).\n    <\/p>\n<p>\n      \u201cInjection drug use is a major factor fueling the global hepatitis C<br \/>\n      crisis, yet people with chronic hepatitis C virus infection who inject<br \/>\n      drugs often remain overlooked and underserved,\u201d said Dr. Ronald Nahass,<br \/>\n      president, ID CARE, New Jersey. \u201cPatients in this study with chronic<br \/>\n      hepatitis C virus infection on opioid agonist therapy, including many<br \/>\n      who continued to use drugs during the trial, were able to complete<br \/>\n      treatment with elbasvir\/grazoprevir and achieve high virologic cure<br \/>\n      rates.\u201d\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105688&amp;esheet=51224839&amp;newsitemid=20151114005005&amp;lan=en-US&amp;anchor=C-EDGE+CO-STAR&amp;index=2&amp;md5=71d1420a23227e67931083ad93642226\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      CO-STAR<\/i><\/a> is a Phase 3 randomized, double-blind,<br \/>\n      placebo-controlled study evaluating treatment with elbasvir\/grazoprevir<br \/>\n      in patients with chronic HCV GT1, 4 or 6 infection who are on OAT (e.g.,<br \/>\n      methadone, buprenorphine). The study randomized 301 patients to one of<br \/>\n      two study arms: an immediate treatment group (ITG) that received<br \/>\n      elbasvir\/grazoprevir (blinded) for 12 weeks (n=201), and a deferred<br \/>\n      treatment group (DTG) that received 12 weeks of placebo (control arm)<br \/>\n      followed by a four-week follow-up period and then elbasvir\/grazoprevir<br \/>\n      (open-label) for 12 weeks (n=100).\n    <\/p>\n<p>\n      The primary efficacy analysis \u2013 or modified full analysis set (mFAS) \u2013<br \/>\n      excluded patients who discontinued treatment for reasons unrelated to<br \/>\n      study drug (n=3) and classified patients who had cleared their baseline<br \/>\n      infection but subsequently acquired a new infection as treatment<br \/>\n      successes (n=5). In the mFAS, 96 percent of GT1a patients (147\/153), 97<br \/>\n      percent of GT1b patients (28\/29), 100 percent of GT4 patients (11\/11)<br \/>\n      and 60 percent of GT6 patients (3\/5) achieved virologic cure when<br \/>\n      treated with elbasvir\/grazoprevir for 12 weeks. Results for patients<br \/>\n      with GT6 infection were limited by the small number of GT6 patients<br \/>\n      enrolled. In a supportive efficacy analysis based on the full analysis<br \/>\n      set (FAS), which included all subjects with HCV GT1, 4 or 6 infection<br \/>\n      who received at least one dose of study drug, the overall SVR12 rate in<br \/>\n      the ITG was 92 percent (184\/201).\n    <\/p>\n<p>\n      Of the 301 patients evaluated across both treatment groups, 76 percent<br \/>\n      had GT1a infection, 21 percent had cirrhosis and 7 percent had HIV\/HCV<br \/>\n      co-infection. All patients were on OAT at baseline. The use of<br \/>\n      non-prescribed drugs, such as cocaine and\/or amphetamines, was observed<br \/>\n      in 59 percent of patients at baseline and remained steady throughout the<br \/>\n      trial; however, adherence to treatment with elbasvir\/grazoprevir was<br \/>\n      high.\n    <\/p>\n<p>\n      In the mFAS, virologic failures occurred in nine patients in the ITG,<br \/>\n      including seven relapses and two discontinuations for reasons deemed<br \/>\n      related to study drug; in the FAS, an additional five reinfections and<br \/>\n      three discontinuations for non-treatment related reasons were counted as<br \/>\n      treatment failures. Across the ITG on active study medication and DTG on<br \/>\n      placebo, four patients (1%) discontinued treatment due to adverse events<br \/>\n      (AE), including two patients (1%) in the ITG and two (2%) in the DTG.<br \/>\n      Two patients (1% across both groups) reported a serious drug-related AE<br \/>\n      (0.5% in the ITG, 1% in the DTG). The most common AEs in the ITG versus<br \/>\n      the DTG, respectively, were fatigue (16% versus 20%), headache (13%<br \/>\n      versus 14%), nausea (11% versus 9%) and diarrhea (10% versus 9%). One<br \/>\n      patient receiving placebo died for reasons unrelated to the study drug.\n    <\/p>\n<p>\n      \u201cLimited research has been conducted in people with chronic hepatitis C<br \/>\n      virus infection undergoing treatment for injection drug use because of<br \/>\n      the perceived challenges and complexities involved in treating this<br \/>\n      population,\u201d said Dr. Eliav Barr, vice president, infectious diseases,<br \/>\n      Merck Research Laboratories. \u201cThis is one of the largest clinical trials<br \/>\n      to date evaluating an all-oral, once-daily, ribavirin-free<br \/>\n      investigational treatment regimen for patients with chronic hepatitis C<br \/>\n      virus infection on opioid agonist therapy and reflects Merck\u2019s ongoing<br \/>\n      commitment to study the diverse real-world population of people living<br \/>\n      with this disease.\u201d\n    <\/p>\n<p>\n      <b>About Chronic HCV Infection and Opioid Agonist Therapy<\/b>\n    <\/p>\n<p>\n      Injection drug use is the most common risk factor for chronic HCV in the<br \/>\n      United States, and rates of transmission and reinfection are higher<br \/>\n      among injection drug users than in other people with HCV.<sup>i,ii<\/sup><br \/>\n      In the United States, 67 percent to 84 percent of this population on OAT<br \/>\n      has been infected with HCV.<sup>iii<\/sup>\n    <\/p>\n<p>\n      <b>About Elbasvir\/Grazoprevir<\/b>\n    <\/p>\n<p>\n      Elbasvir\/grazoprevir is Merck\u2019s investigational, once-daily, fixed-dose<br \/>\n      combination therapy containing elbasvir (HCV NS5A replication complex<br \/>\n      inhibitor) and grazoprevir (HCV NS3\/4A protease inhibitor). Merck\u2019s<br \/>\n      broad clinical trials program includes evaluations of<br \/>\n      elbasvir\/grazoprevir with or without ribavirin for multiple HCV<br \/>\n      genotypes, together with patients with difficult-to-treat conditions,<br \/>\n      such as cirrhosis, advanced chronic kidney disease, HIV\/HCV<br \/>\n      co-infection, inherited blood disorders and those on opioid agonist<br \/>\n      therapy. In July 2015, the U.S. Food and Drug Administration (FDA)<br \/>\n      granted Priority Review for the New Drug Application for<br \/>\n      elbasvir\/grazoprevir with a Prescription Drug User Fee Act (PDUFA)<br \/>\n      action date of Jan. 28, 2016.\n    <\/p>\n<p>\n      In April 2015, the FDA granted Breakthrough Therapy Designation for<br \/>\n      elbasvir\/grazoprevir for the treatment of patients with chronic HCV GT1<br \/>\n      infection with end stage renal disease on hemodialysis, and Breakthrough<br \/>\n      Therapy Designation for elbasvir\/grazoprevir for the treatment of<br \/>\n      patients with chronic HCV GT4 infection. Breakthrough Therapy<br \/>\n      Designation is intended to expedite the development and review of a<br \/>\n      candidate that is planned for use, alone or in combination, to treat a<br \/>\n      serious or life-threatening disease or condition when preliminary<br \/>\n      clinical evidence indicates that the drug may demonstrate substantial<br \/>\n      improvement over existing therapies on one or more clinically<br \/>\n      significant endpoints.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For nearly 30 years, Merck has been at the forefront of the response to<br \/>\n      the HCV epidemic. Merck employees are dedicated to applying their<br \/>\n      scientific expertise, resources and global reach to deliver innovative<br \/>\n      healthcare solutions that support people living with HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51224839&amp;newsitemid=20151114005005&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=977c8d62ee68d434d762d4dab0a0cc57\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51224839&amp;newsitemid=20151114005005&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=4943aac7328c702c0489b5f55f6293d8\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51224839&amp;newsitemid=20151114005005&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=1160abefaf8b9dcc6f35736322a21f65\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51224839&amp;newsitemid=20151114005005&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=25a7fe654abbd76b1041b0a2cd49f835\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51224839&amp;newsitemid=20151114005005&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=b08abfdcfec97243aa661d9606300228\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co. Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51224839&amp;newsitemid=20151114005005&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=4a92ca46accc6ef51487b4622c5ba8fc\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          _______________\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n<p class=\"bwcellpmargin\">\n            <sup>1<\/sup> Elbasvir is an HCV NS5A replication complex inhibitor<br \/>\n            and grazoprevir is an HCV NS3\/4A protease inhibitor.\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignl\">\n<p class=\"bwcellpmargin\">\n            <sup>i<\/sup> CDC (2015). Hepatitis C FAQs for Health<br \/>\n            Professionals. &lt;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fhcv%2Fhcvfaq.htm&amp;esheet=51224839&amp;newsitemid=20151114005005&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fhcv%2Fhcvfaq.htm&amp;index=9&amp;md5=c29ebfc8724ff1afdb7a5811cad03b49\" rel=\"nofollow\">http:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm<\/a>&gt;.\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <sup>ii<\/sup> Grady BP et al. Hepatitis C virus reinfection<br \/>\n            following treatment among people who use drugs. Clin Infect Dis.<br \/>\n            2013 Aug;57 Suppl 2:S105-10.\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <sup>iii<\/sup> CDC (2002). Methadone Maintenance Treatment.\n          <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151114005005r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Doris Li, 908-246-5701<br \/>Sarra        Herzog, 201-669-6570<br \/>or<br \/>Investor Contacts:<br \/>Teri Loxam,        908-740-1986<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company\u2019s Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir\/grazoprevir 1 (50mg\/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Ninety-five percent (189\/198) of patients treated with elbasvir\/grazoprevir for 12 weeks in the pre-specified primary efficacy analysis population achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, considered virologic cure). Adherence to treatment was high, with 97 percent of patients taking at least 95 percent of their study medication over the 12 weeks of therapy. These findings will be featured today at the American Association for the Study of Liver Diseases\u2019 President\u2019s Press Conference at The Liver Meeting\u00ae and<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745075","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir\/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir\/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company\u2019s Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir\/grazoprevir 1 (50mg\/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Ninety-five percent (189\/198) of patients treated with elbasvir\/grazoprevir for 12 weeks in the pre-specified primary efficacy analysis population achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, considered virologic cure). Adherence to treatment was high, with 97 percent of patients taking at least 95 percent of their study medication over the 12 weeks of therapy. These findings will be featured today at the American Association for the Study of Liver Diseases\u2019 President\u2019s Press Conference at The Liver Meeting\u00ae and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\\\/\",\"name\":\"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir\\\/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-11-15T00:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir\\\/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir\/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir\/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company\u2019s Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir\/grazoprevir 1 (50mg\/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Ninety-five percent (189\/198) of patients treated with elbasvir\/grazoprevir for 12 weeks in the pre-specified primary efficacy analysis population achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, considered virologic cure). Adherence to treatment was high, with 97 percent of patients taking at least 95 percent of their study medication over the 12 weeks of therapy. These findings will be featured today at the American Association for the Study of Liver Diseases\u2019 President\u2019s Press Conference at The Liver Meeting\u00ae and","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:47+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/","name":"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir\/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-11-15T00:00:00+00:00","dateModified":"2025-11-07T06:24:47+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvir-grazoprevir-in-people-with-chronic-hepatitis-c-genotypes-1-4-or-6-infection-who-inject-drugs-and-are-on-opioid-agonist-ther\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir\/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"fe6ae628-2ba1-4104-8093-3a4877ed5c5b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Presentation-of-Phase-3-Results-of-Investigational-ElbasvirGrazoprevir-in-People-with-Chronic-Hepatitis-C-Genotypes-1-6NHFV.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745075\/revisions"}],"predecessor-version":[{"id":3674571,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745075\/revisions\/3674571"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745075"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}